Oculis Holding AG (OCS) Cash from Operations Growth (1y) (2023 - 2026)

Oculis Holding AG (OCS) Cash from Operations Growth (1y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 7.14%
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn - -
3 Akari Therapeutics 1,045.06 Bn 1,045.06 Bn - -
4 BeOne Medicines 470.64 Bn 465.84 Bn 1.35 Bn 356.73%
5 Vertex Pharmaceuticals 122.91 Bn 115.67 Bn 2.59 Bn 74.39%
6 Regeneron Pharmaceuticals 70.07 Bn 61.31 Bn 3.31 Bn 3.23%
7 Belite Bio 62.77 Bn 62.77 Bn - -
8 Argenx Se 56.21 Bn 51.02 Bn 1.41 Bn -
9 Revolution Medicines 37.60 Bn 37.60 Bn - -
10 Alnylam Pharmaceuticals 37.34 Bn 34.33 Bn 959.66 Mn 158.60%

Historic Data

Download Data
DateValue
Mar 31, 2026 7.14%
Dec 31, 2025 -71.77%
Sep 30, 2025 -34.38%
Jun 30, 2025 -37.07%
Mar 31, 2025 -34.18%
Dec 31, 2024 24.15%
Sep 30, 2024 7.96%
Jun 30, 2024 -3.26%
Mar 31, 2024 6.92%
Dec 31, 2023 -136.21%
Sep 30, 2023 -89.05%